The USDA Center for Veterinary Biologics has granted Huvepharma approval for the manufacturing and sale of a new broiler-breeder coccidiosis vaccine, Advent® P, which contains Eimeria necatrix and E. brunetti.
“This vaccine was specifically designed to address issues faced by broiler-breeders and commercial layer producers, closing a gap in coccidiosis coverage for our customers,” said David Smith, DVM, Huvepharma’s Director of Poultry Technical Services.
Coccidiosis is a prolific and costly intestinal disease that can be found in all production animal species. In the broiler-breeder industry, coccidiosis negatively impacts multiple facets, including production efficiency, therapeutic costs and bird mortality. Advent P represents an additional coccidiosis solution for the poultry industry.
“Completing the Advent portfolio with Advent P is an exciting advancement for our poultry team and the entirety of Huvepharma,” said Daniel Lackey, Director of Product Management and Marketing with Huvepharma.
Advent P will be available for purchase within the coming months. The vaccine has a shelf life of 9 months and will be packaged in 10 x 10,000-dose clamshells. It can be applied by spray cabinet at day of age or on feed.
For more information, please visit www.huvepharma.us.
Editor’s note: Content on Modern Poultry’s Industry Insights pages is provided and/or commissioned by our sponsors, who assume full responsibility for its accuracy and compliance.
